Poor medication adherence is a pervasive issue with considerable health and
socioeconomic consequences. Although the underlying reasons are generally understood …

Covalent inhibitors are recognized as an important component in drug discovery and
therapeutics. Since the first appearance of covalent inhibitors in the late 18th century, the …

Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab …

Purpose Widespread antibiotic-resistant bacteria are threatening the arsenal of existing
antibiotics. Not only are antibiotics less likely to be effective today, but their extensive use …

At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control
(HbA1c< 7%). One of the major contributing factors is poor medication adherence. Poor …

(AGA) on the management of mild-to-moderate ulcerative colitis (UC). The guideline was
developed by the AGA Institute's Clinical Guidelines Committee and approved by the AGA …

Introducción: la falta de adherencia al tratamiento en el contexto de las enfermedades
crónicas es considerada como un grave problema de salud. Objetivo: examinar los …

Objetivos: Describir los factores que pueden influir en la adherencia a los tratamientos
farmacológicos y las intervenciones que han sido desarrolladas para su mejora. Métodos …

Background Poor adherence may have a major impact on clinical outcome, contributing to
substantial worsening of disease, increased health care costs and even death. With …

Background: In previous studies, teriflunomide significantly reduced the annualised relapse
rate (ARR) and disability progression. Objective: This phase 3, rater-blinded study …